Previous 10 | Next 10 |
home / stock / abscf / abscf news
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PROTECTION STRATEGY BASED ON MEDICAL USE PATENTS Pa...
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET Paris, 28 november, 2023, 7.15pm CET AB Science SA (Euronext – FR0010557264 – AB) will host a li...
PRESS RELEASE THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)". THIS PROGRAM WILL FUND A MASITINIB PHASE 2 CLINICAL TRIAL ...
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORM ATION FOR THE FIRST HALF OF 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development strategy based on two platforms: the late-stage masitinib platform and the new microtubule platform Mas...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOT RO PHIC LATERAL SCLEROSIS BASED ON THE UPDATED TIMETABLE, A...
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER ( mCRPC ) , STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION...
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) WITH PROTECTION UNTIL 203 7 CANADIAN PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE F OR ALS ACRO...
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 202 3 ALS DRUG DEVELOPMENT SUMMIT (BOSTON, USA) Paris, 17 May , 202 3 , 8 :00 pm CET AB Scie...
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS , FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris, 09 May , ...
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 202 2 AND THE KEY EVENTS OF THE PERIOD Financial information and other corporate information Consolidated operating loss of €15.9 million as of 31 December 2022, c...
News, Short Squeeze, Breakout and More Instantly...
Ab Science Paris Ord Company Name:
ABSCF Stock Symbol:
OTCMKTS Market:
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with the European Medicines Agency (EMA) and Health Cana...
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A EUROPEAN PATENT FOR MASITINIB IN THE TREATMENT OF SEVERE MASTOCYTOSIS WITH PROTECTION UNTIL 2036 Paris, May 13, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European patent office has...
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS THIS PUBLICATI...